CY1109480T1 - ΠΡΩΤΕΪΝΕΣ ΣΥΝΔΕΣΗΣ Gag - Google Patents

ΠΡΩΤΕΪΝΕΣ ΣΥΝΔΕΣΗΣ Gag

Info

Publication number
CY1109480T1
CY1109480T1 CY20091101039T CY091101039T CY1109480T1 CY 1109480 T1 CY1109480 T1 CY 1109480T1 CY 20091101039 T CY20091101039 T CY 20091101039T CY 091101039 T CY091101039 T CY 091101039T CY 1109480 T1 CY1109480 T1 CY 1109480T1
Authority
CY
Cyprus
Prior art keywords
site
gag binding
proteins gag
protein
gag
Prior art date
Application number
CY20091101039T
Other languages
English (en)
Inventor
Andreas J Kungl
Original Assignee
Protaffin Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protaffin Biotechnologie Ag filed Critical Protaffin Biotechnologie Ag
Publication of CY1109480T1 publication Critical patent/CY1109480T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Παρέχεται μέθοδος για εισαγωγή μιας θέσης σύνδεσης GAG σε μία πρωτεΐνη που περιλαμβάνει τα στάδια: -πιστοποίησης μιας περιοχής σε μία πρωτεΐνη η οποία δεν είναι βασική για διατήρηση της δομής, -εισαγωγή τουλάχιστον ενός βασικού αμινοξέος εντός της εν λόγω θέσης ή/και απαλοιφής τουλάχιστον ενός ογκώδους ή/και όξινου αμινοξέος στην εν λόγω θέση, όπου η εν λόγω θέσης σύνδεσης GAG έχει συνάφεια σύνδεσης GAG Kd≤10 μΜ, κατά προτίμηση ≤1 μΜ, ακόμη προτιμότερα ≤0,1 μΜ, καθώς επίσης τροποποιημένες πρωτεΐνες σύνδεσης GAG.
CY20091101039T 2003-12-04 2009-10-08 ΠΡΩΤΕΪΝΕΣ ΣΥΝΔΕΣΗΣ Gag CY1109480T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0195203A AT412785B (de) 2003-12-04 2003-12-04 Gag-bindungsproteine
EP06117339A EP1752470B1 (en) 2003-12-04 2004-12-02 Gag binding proteins

Publications (1)

Publication Number Publication Date
CY1109480T1 true CY1109480T1 (el) 2014-08-13

Family

ID=33494536

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091101039T CY1109480T1 (el) 2003-12-04 2009-10-08 ΠΡΩΤΕΪΝΕΣ ΣΥΝΔΕΣΗΣ Gag
CY20111100904T CY1112330T1 (el) 2003-12-04 2011-09-16 Πρωτεϊνες συνδεσης gag

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100904T CY1112330T1 (el) 2003-12-04 2011-09-16 Πρωτεϊνες συνδεσης gag

Country Status (20)

Country Link
US (4) US7585937B2 (el)
EP (5) EP1689775B1 (el)
JP (3) JP4980721B2 (el)
KR (2) KR101188785B1 (el)
CN (1) CN1890264B (el)
AT (3) AT412785B (el)
AU (1) AU2004295104B2 (el)
BR (1) BRPI0416544A (el)
CA (1) CA2546789A1 (el)
CY (2) CY1109480T1 (el)
DE (1) DE602004022595D1 (el)
DK (2) DK1752470T3 (el)
ES (2) ES2330362T3 (el)
IL (1) IL175565A0 (el)
NZ (1) NZ547612A (el)
PL (2) PL1752470T3 (el)
PT (2) PT1752470E (el)
SG (1) SG149000A1 (el)
SI (2) SI1689775T1 (el)
WO (1) WO2005054285A1 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
EP1937815B1 (en) 2005-09-13 2015-05-13 National Research Council of Canada Methods and compositions for modulating tumor cell activity
CN100366637C (zh) * 2005-11-17 2008-02-06 中国人民解放军第四军医大学 人白细胞介素8拮抗蛋白及其制备方法
US9422356B2 (en) * 2006-01-31 2016-08-23 Republic Of Korea (Republic Of National Fisheries Research And Development Institute) Artificial signal peptide for expressing an insoluble protein as a soluble active form
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
EP1894571A1 (en) * 2006-08-29 2008-03-05 Protaffin Biotechnologie AG Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection
WO2008140500A2 (en) * 2006-12-08 2008-11-20 The University Of Miami Hyaluronidase inhibitors as anti-cancer agents
AT504685B1 (de) * 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
AU2008287530A1 (en) * 2007-05-07 2009-02-19 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
EP2042516A1 (en) * 2007-09-27 2009-04-01 Protaffin Biotechnologie AG Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same
EP2185719B1 (en) * 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
EP2053060A1 (en) * 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-based glyocosaminoglycan antagonists and methods of using same
US8314212B2 (en) 2008-02-08 2012-11-20 Lindsey Miles Plasminogen receptor PLG-RKT and antibodies thereof
JP2012516143A (ja) 2009-01-30 2012-07-19 プロットアフィン ビオテヒノロギー アクチエンゲゼルシャフト グリコサミノグリカンを拮抗するｍｃｐ−１突然変異体およびその使用方法
KR20120080196A (ko) 2009-09-11 2012-07-16 프로타핀 바이오테크놀로기 아게 Ｃｘｃｌ８-매개의 폐 염증을 치료하는 조성물
DK2504363T3 (da) 2009-11-24 2019-07-29 Alethia Biotherapeutics Inc Anti-clusterin-antistoffer og antigenbindende fragmenter og deres anvendelse til reducering af tumorvolumen
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
WO2012123585A1 (en) 2011-03-16 2012-09-20 Protaffin Biotechnologie Ag Fgfr1-based antagonists with improved glycosaminoglycan affinity and methods of using same
EP2729487A2 (en) 2011-07-08 2014-05-14 Protaffin Biotechnologie AG Novel sdf-1-based glycosaminoglycan antagonist and methods of using same
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2014079957A1 (de) * 2012-11-23 2014-05-30 Bayer Cropscience Ag Selektive inhibition der ethylensignaltransduktion
KR101457371B1 (ko) * 2013-01-10 2014-11-04 강원대학교산학협력단 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물
EP3096776B1 (en) 2014-01-22 2020-12-02 Antagonis Biotherapeutics GmbH Novel glycosaminoglycan-antagonising fusion proteins and methods of using same
WO2021038033A1 (en) 2019-08-29 2021-03-04 Antagonis Biotherapeutics Gmbh T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity
CN110791523B (zh) * 2019-12-13 2022-05-10 南京农业大学 一种棉花抗旱相关基因GhRCHY1及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960691A (en) * 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation
WO1992007935A1 (en) * 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
DK0607777T3 (da) * 1993-01-08 1999-08-16 Hoechst Ag Anvendelse af leflunomid til inhibering af interleukin 8
JP2694321B2 (ja) * 1993-03-10 1997-12-24 大塚製薬株式会社 インターロイキン−１阻害剤
US5527546A (en) * 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
US5866402A (en) 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
JPH1045602A (ja) * 1996-07-31 1998-02-17 Motoyasu Murakami ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−８産生阻害剤
US6852696B2 (en) * 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
IL154696A (en) * 2000-09-05 2008-11-03 Biosight Ltd Peptide conjugated anti-cancer prodrugs
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
JP2003063980A (ja) * 2001-08-28 2003-03-05 Noevir Co Ltd Ｒａｎｔｅｓ産生阻害剤
US6982170B1 (en) * 2001-12-17 2006-01-03 Maine Medical Center Research Institute Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
JP2003306438A (ja) * 2002-02-18 2003-10-28 Shiseido Co Ltd ケモカイン発現阻害剤
JP2003267887A (ja) * 2002-03-15 2003-09-25 Shiseido Co Ltd ケモカイン発現抑制皮膚外用剤
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
MXPA04009874A (es) * 2002-04-10 2005-10-19 Applied Research Systems Antagonistas novedosos de proteinas mcp.
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine

Also Published As

Publication number Publication date
US20080112926A1 (en) 2008-05-15
EP1689775B1 (en) 2011-07-06
SI1752470T1 (sl) 2009-12-31
ES2369139T3 (es) 2011-11-25
PL1689775T3 (pl) 2011-12-30
ES2330362T3 (es) 2009-12-09
ATE439376T1 (de) 2009-08-15
EP1752470B1 (en) 2009-08-12
EP2311866A1 (en) 2011-04-20
WO2005054285A1 (en) 2005-06-16
KR20120063542A (ko) 2012-06-15
US7585937B2 (en) 2009-09-08
KR101188785B1 (ko) 2012-10-16
EP2270038A3 (en) 2011-02-23
US7807413B2 (en) 2010-10-05
BRPI0416544A (pt) 2007-01-09
DK1689775T3 (da) 2011-09-26
EP2363411A1 (en) 2011-09-07
NZ547612A (en) 2009-07-31
US20090005541A1 (en) 2009-01-01
PT1752470E (pt) 2009-10-15
ATA19522003A (de) 2004-12-15
KR20070001917A (ko) 2007-01-04
CN1890264A (zh) 2007-01-03
AU2004295104A1 (en) 2005-06-16
US20110144305A1 (en) 2011-06-16
DK1752470T3 (da) 2009-12-14
PT1689775E (pt) 2011-10-13
JP2012139226A (ja) 2012-07-26
EP2270038A2 (en) 2011-01-05
KR101278459B1 (ko) 2013-07-01
EP1752470A1 (en) 2007-02-14
CN1890264B (zh) 2014-01-22
US20100331237A1 (en) 2010-12-30
IL175565A0 (en) 2006-09-05
SG149000A1 (en) 2009-01-29
JP2007536906A (ja) 2007-12-20
DE602004022595D1 (de) 2009-09-24
JP4980721B2 (ja) 2012-07-18
PL1752470T3 (pl) 2010-01-29
CY1112330T1 (el) 2015-12-09
AU2004295104B2 (en) 2010-07-22
AT412785B (de) 2005-07-25
CA2546789A1 (en) 2005-06-16
ATE515269T1 (de) 2011-07-15
JP2012165747A (ja) 2012-09-06
SI1689775T1 (sl) 2011-11-30
EP1689775A1 (en) 2006-08-16

Similar Documents

Publication Publication Date Title
CY1109480T1 (el) ΠΡΩΤΕΪΝΕΣ ΣΥΝΔΕΣΗΣ Gag
CY1117551T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
CY1119106T1 (el) Αντισωματα εναντι masp-2
CY1114944T1 (el) Σταθεροποιημενα αλφα ελικοειδη πεπτιδια και χρησεις αυτων
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE499382T1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
ATE442348T1 (de) Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
WO2004009774A3 (en) Protein conjugates with a water-soluble biocompatible, biogradable polymer
DE60035337D1 (de) Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken
CY1105452T1 (el) Παραγωγα της κυκλοσπορινης και μεθοδος παρασκευης των εν λογω παραγωγων
CY1106003T1 (el) Παραγωγα του ν-βενζοϋλοουρεϊδο-κινναμωμικου οξεος, μεθοδος για την παρασκευη τους και η χρηση τους
FR2827866B1 (fr) Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
DE60013021D1 (de) Herstellung von S,S und R,S Aminosäuren-Isosteren
ATE365748T1 (de) Polymer-konjugate von neublastin und methoden für deren verwendung
DE60335726D1 (de) Chromoprotein und fluoroproteine
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
ATE374246T1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter